8SAS image
Entry Detail
PDB ID:
8SAS
EMDB ID:
Title:
CryoEM structure of DH270.5-CH848.10.17
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2023-04-01
Release Date:
2023-04-19
Method Details:
Experimental Method:
Resolution:
4.00 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:CH848.10.17 gp120
Chain IDs:A, E (auth: F), I (auth: K)
Chain Length:463
Number of Molecules:3
Biological Source:HIV-1 06TG.HT008
Polymer Type:polypeptide(L)
Description:CH848.10.17 gp41
Chain IDs:B, F (auth: G), J (auth: L)
Chain Length:132
Number of Molecules:3
Biological Source:HIV-1 06TG.HT008
Polymer Type:polypeptide(L)
Description:DH270.5 variable heavy chian
Chain IDs:C, G (auth: H), K (auth: M)
Chain Length:127
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:DH270.5 variable light chain
Chain IDs:D, H (auth: I), L (auth: N)
Chain Length:111
Number of Molecules:3
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage.
Nat Commun 14 2782 2782 (2023)
PMID: 37188681 DOI: 10.1038/s41467-023-38108-1

Abstact

Antibody affinity maturation enables adaptive immune responses to a wide range of pathogens. In some individuals broadly neutralizing antibodies develop to recognize rapidly mutating pathogens with extensive sequence diversity. Vaccine design for pathogens such as HIV-1 and influenza has therefore focused on recapitulating the natural affinity maturation process. Here, we determine structures of antibodies in complex with HIV-1 Envelope for all observed members and ancestral states of the broadly neutralizing HIV-1 V3-glycan targeting DH270 antibody clonal B cell lineage. These structures track the development of neutralization breadth from the unmutated common ancestor and define affinity maturation at high spatial resolution. By elucidating contacts mediated by key mutations at different stages of antibody development we identified sites on the epitope-paratope interface that are the focus of affinity optimization. Thus, our results identify bottlenecks on the path to natural affinity maturation and reveal solutions for these that will inform immunogen design aimed at eliciting a broadly neutralizing immune response by vaccination.

Legend

Protein

Chemical

Disease

Primary Citation of related structures